



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 10

Complete if Known

Application Number	10/715,810
Filing Date	November 17, 2003
First Named Inventor	Shengwen Li
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	ALLE0004-100 (17614(BOT))

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
CMK	AA	US-6,458,365	10/01/2002	Aoki et al	
	AB	US- 5,766,605	06/16/1998	Sanders et al	
	AC	US- 5,714,468	02/03/1998	Dao	
	AD	US- 6,464,986	10/15/2002	Aoki et al	
	AE	US- 6,113,915	09/05/2000	Aoki et al	
	AF	US- 6,306,403	10/23/2001	Donovan	
	AG	US- 6,289,893	10/09/2001	Schwartz et al	
	AH	US- 5,670,484	09/23/1997	Binder	
	AI	US- 6,423,319	07/23/2002	Brooks et al	
	AJ	US- 6,139,845	10/31/2000	Donovan	
	AK	US- 6,143,306	11/07/2000	Donovan	
	AL	US- 5,437,291	08/01/1995	Pasricha et al	
	AM	US- 6,365,164	04/02/2002	Schmidt	
	AN	US- 6,063,768	05/16/2000	First	
	AO	US- 6,395,277	05/28/2002	Graham	
	AP	US- 6,285,379	07/24/2001	Donovan	
	AQ	US- 6,358,513	03/19/2002	Voet et al	
	AR	US- 6,328,977	12/11/2001	Donovan	
	AS	US- 6,306,423	10/23/2001	Donovan	
	AT	US- 6,312,708	11/08/2001	Donovan	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
CMK	EE	WO02/089834	11/04/02	Imperial College Inovations		

Examiner Signature	<i>CHL</i>	Date Considered	2/16/05
-----------------------	------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

APR 12 2004

PTO/SB/08a (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	2	of	10
-------	---	----	----

Complete if Known

Application Number	10/715,810
Filing Date	November 17, 2003
First Named Inventor	Shengwen Li
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	ALLE0004-100 (17614(BOT))

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

Chapman


Date Considered

5016/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b(05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 10

Complete if Known

Application Number	10/715,810
Filing Date	November 17, 2003
First Named Inventor	Shengwin Li
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	ALLE0004-100 (17614(BOT))

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CHK	AU	PARK and SIMPSON, "Inhalational poisoning by botulinum toxin and inhalation vaccination with its heavy-chain component," Infect. Immun. (2003) 71:1147-1154.	
	AV	ATASSI and OSHIMA, "Structure, activity and immune (T and B cell) recognition of botulinum neurotoxins," Crit. Rev. Immunol. (1999) 19:219-260.	
	AW	MARCHESE RAGONA, et al., "Management of parotid sialoceles with botulinum toxin," The Laryngoscope (1999) 109:1344-1346.	
	AX	WIEGAND, et al., "125-I labelled botulinum A neurotoxin: pharmacokinetics in cats after intramuscular injection," Naunyn-Schmiedeberg's Arch. Pharmacol. (1976) 282:161-165.	
	AY	HABERMANN, "125-I labeled neurotoxin from Clostridium botulinum A: preparation, binding to synaptosomes and ascent to the spinal cord," Naunyn-Schmiedeberg's Arch. Pharmacol. (1974) 281:47-58.	
	AZ	MOYER, et al., "Botulinum Toxin Type B: Experimental and Clinical Experience," in Therapy with Botulinum Toxin, Jankovic, ed., 1994, pp 71-84.	
	BA	GONELLE-GISPERT, "SNAP-25a and -25b isoforms are both expressed in insulin secreting cells and can function in insulin secretion," Biochem. J. (1999) 339:159-165.	
	BB	International Conference on Botulinum Toxin: Basic Science and Clinical Therapeutics," Mov. Disord. (1995) 10:381-408.	
	BC	HABERMAN, et al., "Tetanus toxin and botulinum A and C neurotoxins inhibit noradrenaline release from cultured mouse brain," J. Neurochem. (1988) 51:522-527.	
	BD	SANCHEZ-PRIETO, et al., "Botulinum toxin A blocks glutamate exocytosis from guinea pig cerebral cortical synaptosomes," Eur. J. Biochem. (1987) 165:675-681.	
CHK	BE	PEARCE, "Pharmacologic characterization of botulinum toxin for basic science and medicine," Toxicon (date) 35:1373-1412.	

Examiner
SignatureDate
Considered

2/16/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b(05-03)

Approved for use through 04/30/2003. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 4 of 10

Complete if Known

Application Number	10/715,810
Filing Date	November 17, 2003
First Named Inventor	Shengwin Li
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	ALLE0004-100 (17614(BOT))

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CMK	BF	BIGALKE, et al., "Botulinum A neurotoxin inhibits non-cholinergic synaptic transmission in mouse spinal cord neurons in culture," Brain Res. (1985) 360:318-324.	
	BG	HABERMANN, "Inhibition by tetanus and botulinum A toxin of the release of [3H] noradrenaline and [3H] GABA from rat brain homogenate," Experientia (1988) 44:224-226.	
	BH	BIGALKE, et al., "Tetanus toxin and botulinum A toxin inhibit release and uptake of various transmitters as studied with particulate preparations from rat brain and spinal cord," Naunyn-Schmiedelberg's Arch. Pharmacol. (1981) 316:244-251.	
	BI	JANCOVIC, et al., eds., "Therapy with Botulinum Toxin," New York, Marcel Dekkar, 1994. p.5.	
	BJ	SCHANTZ, et al., "Properties and use of botulinum toxin and other microbial neurotoxins in medicine," Microbial Rev. (1992) 56:80-99.	
	BK	SLOOP, et al., "Reconstituted botulinum toxin type A does not lose potency in humans if it is refrozen or refrigerated for two weeks before use," Neurology (1997) 48:249-253.	
	BL	GALBIATI, et al., "Identification, sequence and developmental expression of Invertebrate flotillins from Drosophila melanogaster," Gene (1998) 210:229-237.	
	BM	LI, et al., "Src tyrosine kinases, Galpha subunits, and H-ras share a common membrane-anchored scaffolding protein, caveolin," J. Biol. Chem. (1996) 271:29182-29190.	
	BN	ISHIZAKA, et al., "Angiotensin II tyhpe receptor: Relationship with caveolae and caveolin after initial agonist simulation," Hypertension (1998) 32:459-466.	
	BO	JU, et al., "Inhibitory interactions of the bradykinin B2 receptor with endothelial nitric-acid synthase," J. Biol. Chem. (1998) 273:24025-24029.	
CMK	BP	WEBB, et al., "SR-BII, an isoform of the scavenger receptor BI containing an alternate cytoplasmic tail, mediates lipid transfer between high density lipoprotein and cells," J. Biol. Chem. (1998) 273:15241-15248.	

Examiner Signature		Date Considered	2/16/05
-----------------------	--	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 5 of 10

Complete if Known

Application Number	10/715,810
Filing Date	November 17, 2003
First Named Inventor	Shengwin Li
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	ALLE0004-100 (17614(BOT))

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CMK	BQ	DRAB, et al., "Loss of caveolae, vascular dysfunction, and primary defects in caveolin-1 gene-disrupted mice," Science (2001) 293:2449-2452.	
	BR	BOUILLLOT, et al., "Axonal amyloid precursor protein expressed by neurons in vitro is present in a membrane fraction with caveolae-like properties," J. Biol. Chem. (1996) 271:7640-7644.	
	BS	RAZANI, et al., "Caveolae: From cell biology to animal physiology," Pharmacol. Rev. (2002) 54:431-467.	
	BT	LI, et al., "Phosphorylation of caveolin by src tyrosine kinases," J. Biol. Chem. (1996) 271:3863-3868.	
	BU	RAZANI and LISANTI, "Caveolin-deficient mice: insights into caveolar function and human disease," J. Clin. Invest. (2001) 108:1553-1561.	
	BV	GARCIA-CARDENA, et al., "Dissecting the interaction between nitric oxide synthase (NOS) and caveolin," J. Biol. Chem. (1997) 272:25437-25440.	
	BW	SOTGIA, et al., "Intracellular retention of glycoposphatidylinositol-linked proteins in caveolin-deficient cells," Mol. Cell. Biol. (2002) 22:3905-3926.	
	BX	FRANK, et al., "Influence of caveolin-1 on cellular cholesterol efflux mediated by high-density lipoproteins," Am. J. Physiol. Cell Physiol. (2001) 280:C1204-C1214.	
	BY	GALBIATI, et al., "Caveolin-1 expression negatively regulates cell cycle progression by inducing G0/G1 arrest via a p53/p21WAF1/Cip1-dependent mechanism," Mol. Biol. Cell. (2001) 12:2229-2244.	
	BZ	FRANK, et al., "Adenovirus-mediated expression of cavolin-1 in mouse liver increases plasma high-density lipoprotein levels," Biochemistry (2001) 40:10892-10900.	
CMK	CA	LEE, et al., "Src-induced phosphorylation of caveolin-2 on tyrosine 19," J. Biol. Chem. (2002) 277:34556-34567.	

Examiner Signature		Date Considered	2/16/05
-----------------------	--	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 6 of 10

Complete if Known

Application Number	10/715,810
Filing Date	November 17, 2003
First Named Inventor	Shengwin Li
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	ALLE0004-100 (17614(BOT))

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CMK	CB	COUET, et al., "Identification of peptide and protein ligands for the caveolin-scaffolding domain," J. Biol. Chem. (1997) 272:6525-6533.	
	CC	LEE, et al., "Constitutive and growth factor-regulated phosphorylation of caveolin-1 occurs at the same site (Tyr-14) in vivo: identification of a c-src/cav-1/grb7 signalling cassette," Mol. Endocrinol. (2000) 14:1750-1775.	
	CD	SATO, et al., "Reconstitution of src-dependent phospholipase Cgamma phosphorylation and transient calcium release by using membrane rafts and cell-free extracts from Xenopus eggs," J. Biol. Chem. (2003) 278:38413-38420.	
	CE	GARGALOVIC and DORY, "Cellular apoptosis is associated with increased caveolin-1 expression in macrophages," J. Lipid Res. (2003) 44:1622-1632	
	CF	HAMER, et al., "Rational design of drugs that induce human immunodeficiency virus replication," J. Virol. (2003) 77:10227-10236.	
	CG	McINTOSH, et al., "Targeting endothelium and its dynamic caveolae for tissue-specific transcytosis in vivo: a pathway to overcome cell barriers to drug and gene delivery," Proc. Natl. Acad. Sci. USA (2002) 99:1998-2001	
	CH	LI, et al., "Baculovirus-based expression of mammalian caveolin in Sf21 insect cells," J. Biol. Chem. (1996) 271:28647-28654.	
	CI	LI, et al., "Expression and characterization of recombinant caveolin," J. Biol. Chem. (1996) 271:568-573.	
	CJ	DOBROSOTSKAYA, et al., "Reconstitution of sterol-regulated endoplasmic reticulum-to-Golgi transport of SREBP-2 in insect cells by co-expression of mammalian SCAP and insigs," J. Biol. Chem. (2003) 278:35837-35843.	
	CK	SCHNITZER, et al., "Endothelial caveolae have the molecular transport machinery for vesicle budding, docking, and fusion including VAMP, NSF, SNAP, annexins and GTPases," J. Biol. Chem. (1995) 270:14399-14404.	
CMK	CL	HAYASHI, et al., "Amyloid precursor protein in unique cholesterol-rich microdomains different from caveolae-like domains," Biochim. Biophys. Acta (2000) 1483:81-80.	

Examiner Signature		Date Considered	7/16/05
-----------------------	---	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 7 of 10

Complete if Known

Application Number	10/715,810
Filing Date	November 17, 2003
First Named Inventor	Shengwin Li
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	ALLE0004-100 (17614(BOT))

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CMK	CM	BANWAIT, et al., "Role of nitric acid in beta(3)-adrenoreceptor activation on basal tone of internal anal sphincter," Am. J. Physiol.-Gastroint. Liver Physiol. (2003) 285:G547-G555.	
	CN	McLOON and CHRISTIANSEN, "Increasing extraocular muscle strength with insulin-like growth factor," Investig. Ophthalmol. Visual Sci. (2003) 44:3866-3872.	
	CO	CARVER and SCHNITZER, "Caveolae: mining little caves for new cancer targets," Nature Reviews Cancer (2003) 3:571-581.	
	CP	SCHNITZER, "Caveolae: from basic trafficking mechanisms to targeting transcytosis for tissue-specific drug and gene delivery in vivo," Adv. Drug. Deliv. Rev. (2001) 28:265-280.	
	CQ	McINTOSH and SCHNITZER, "Caveolae require intact VAMP for targeted transport in vascular endothelium," Am. J. Physiol. (1999) 277:H2222-H2232.	
	CR	LEE, et al., "Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells," Oncogene (1998) 16:1391-1397.	
	CS	PAJVANI, et al., "Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity," J. Biol. Chem. (2003) 278:9073-9085.	
	CT	MYNARCIK, et al., "Adiponectin and leptin levels in HIV-infected subjects with insulin resistance and body fat redistribution," J. Acquir. Immun. Defic. Syndr. (2002) 31:514-520.	
	CU	RAJALA, et al., "Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production," J. Clin. Invest. (2003) 11:225-230.	
	CV	MENZAGHI, et al., "A haplotype at the adiponectin locus is associated with obesity and other features of the insulin resistance syndrome," Diabetes (2002) 51:2306-2312.	
CMK	CW	IYENGAR, et al., "Adipocyte-secreted factors synergistically promote mammary tumorigenesis through induction of anti-apoptotic transcriptional programs and proto-oncogene stabilization," Oncogene (2003) 22:6408-6423.	

Examiner Signature		Date Considered	2/16/05
-----------------------	---	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 8 of 10

Complete if Known

Application Number	10/715,810
Filing Date	November 17, 2003
First Named Inventor	Shengwin Li
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	ALLE0004-100 (17614(BOT))

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CMK	CX	COHEN, et al., "Role of caveolin and caveolae in insulin signaling and diabetes," Am. J. Physiol. Endocrinol. Metab. (2003) 285:E1151-E1160.	
	CY	KRATCHMAROVA, et al., "A proteomic approach for identification of secreted proteins during the differentiation of 3T3-L1 preadipocytes to adipocytes," Mol. Cell. Proteomics (2002) 1:213-222.	
	CZ	COMBS, et al., "Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization," Endocrinology (2002) 143:998-1007.	
	DA	BERG, et al., "ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism," Trends Endocrinol. Metab. (2002) 13:84-89.	
	DB	COMBS, et al., "Endogenous glucose production is inhibited by the adipose-derived protein Acrp30," J. Clin. Invest. (2001) 108:1875-1881.	
	DC	RAZANI, et al., "Caveolin-1-deficient mice are lean, resistant to diet-induced obesity, and show hypertriglyceridemia with adipocyte abnormalities," J. Biol. Chem. (2002) 277:8635-8647.	
	DD	SHIN, et al., "Involvement of cellular caveolae in bacterial entry into mast cells," Science (2000) 289:785-788.	
	DE	BURGUENO, et al., "Metabotropic glutamate type 1alpha receptor localizes in low-density caveolin-rich plasma membrane fractions," J. Neurochem. (2003) 86:785-791.	
	DF	TANG, et al., "Expression of metabotropic glutamate receptor 1alpha in the hippocampus of rat pilocarpine model of status epilepticus," Epilepsy Res. (2001) 46:179-189.	
	DG	CIRUELA, et al., "Metabotropic glutamate 1alpha and adenosine A1 receptors assemble into functionally interacting complexes," J. Biol. Chem. (2001) 276:18345-18351.	
CMK	DH	ZHANG, et al., "Localization and regulation of the delta-opioid receptor in dorsal root ganglia and spinal cord of the rat and monkey: evidence for association with the membrane of large dense-core vesicles," Neuroscience (1998) 82:1225-1242.	

Examiner Signature		Date Considered	2/16/05
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 9 of 10

Complete if Known

Application Number	10/715,810
Filing Date	November 17, 2003
First Named Inventor	Shengwin Li
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	ALLE0004-100 (17614(BOT))

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CMK	DI	SKOFF, et al., "Nerve growth factor (NF) and glial cell line-derived neurotrophic factor (GDNF) regulate substance P release in adult spinal sensory neurons," Neurochem. Res. (2003) 28:847-854.	
	DJ	SCHAIBLE, et al., "Mechanisms of pain in arthritis," Ann. NY Acad. Sci. (2002) 966:343-354.	
	DK	XU, et al., "On the role of galanin, substance P and other neuropeptides in primary sensory neurons of the rat: studies on spinal reflex excitability and peripheral axotomy," Eur. J. Neurosci. (1990) 2:733-743.	
	DL	TREVISANI, et al., "Ethanol elicits and potentiates nociceptor responses via the vanilloid receptor," Nat. Neurosci. (2002) 5:546-551.	
	DM	MALCANGIO, et al., "A novel control mechanism based on GDNF modulation of somatostatin release from sensory neurones," FASEB J. (2002) 16:730-732.	
	DN	SOUTHALL, et al., "Twenty-four hour exposure to prostaglandin down regulates prostanoid receptor binding but does not alter PGE(2)-mediated sensitization or rat sensory neurons," Pain (2002) 96:285-296.	
	DO	MARVIZON, et al., "Neurokinin 1 receptor internalization in spinal cord slices induce by dorsal root stimulation is mediated by NMDA receptors," J. Neurosci. (1997) 17:8129-8138.	
	DP	MORIOKA, et al., "Interleukin-1beta-induced substance P release from rat cultured primary afferent neurons driven by two phospholipase A2 enzymes: secretory type IIA and cystolic type IV," J. Neurochem. (2002) 80:989-997.	
	DQ	ALLEN, et al., "Noxious cutaneous thermal stimuli induce a graded release of endogenous substance P in the spinal cord: imaging peptide action in vivo," J. Neurosci. (1997) 17:5921-5927.	
	DR	HARRIS, et al., "Expression of caveolin by bovine lymphocytes and antigen-presenting cells," Immunology (2002) 105:190-195.	
CMK	DS	SHIN and ABRAHAM, "Glycosylphosphatidylinositol-anchored receptor-mediated bacterial endocytosis," FEMS Microbiol. Lett. (2001) 197:131-138.	

Examiner Signature		Date Considered	2/16/05
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 10 of 10

Complete if Known

Application Number	10/715,810
Filing Date	November 17, 2003
First Named Inventor	Shengwin Li
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	ALLE0004-100 (17614(BOT))

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CHK	DT	FIELD, et al., "Fc epsilon RI-mediated recruitment of p53/56lyn to detergent resistant membrane domains accompanies cellular signalling," Proc. Natl. Acad. Sci. USA (1995) 92:9201-9205.	
	DU	BAIG, et al., "Agonist activated adrenocorticotropin receptor internalizes via a clathrin-mediated G protein receptor kinase dependent mechanism," Endocrin. Res. (2002) 28:281-289.	
	DV	KOHNO, et al., "N-glycans of sphingosine 1-phosphate receptor Edg-1 regulate ligand-induced receptor internalization," FASEB J. (2002) 16:983-992.	
	DW	DALE, et al., "Agonist-stimulated and tonic internalization of metabotropic glutamate receptor 1a in human embryonic kidney 293 cells: agonist-stimulated endocytosis is beta-arrestin 1 isoform-specific," Mol. Pharmacol. (2001) 60:1243-1253.	
	DX	OSTROM, et al., "Receptor number and caveolar co-localization determine receptor coupling efficiency to adenylyl cyclase," J. Biol. Chem. (2001) 276:42063-42069.	
	DY	OSTROM, et al., "Stoichiometry and compartmentation in G protein-coupled receptor signalling: implications for therapeutic interventions involving G(s)," J. Pharmacol. Exp. Ther. (2000) 294:407-412.	
	DZ	RIDDELL, et al., "Compartmentalization of beta-secretase (Asp20) into low-bouyant density, noncaveolar lipid rafts," Curr. Biol. (2001) 11:1288-1293.	
	EA	ROUVINSKI, et al., "Both raft- and non-raft proteins associate with CHAPS-insoluble complexes: some APP in large complexes," Biochem. Biophys. Res. Comm. (2003) 308:750-758.	
CHK	EB	IKEZU, et al., "Caveolae, plasma membrane microdomains for alpha-secretase-mediated processing of the amyloid secretory protein," J. Biol. Chem. (1998) 273:10485-10495.	

Examiner Signature		Date Considered	9/16/05
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.